Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.

Researchers have unveiled a new DNA-based therapy that silences the PCSK9 gene to lower cholesterol without statin side effects. Early results show dramatic reductions in cholesterol levels, offering ...

Doctors often prescribe cholesterol-lowering drugs to help people stay healthy as they get older. These medicines are mainly ...

Scientists at the University of Barcelona have unveiled a DNA-based therapy that dramatically lowers cholesterol by targeting ...

An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional ...

Scientists think those cholesterol-lowering statins might be doing something else we didn't know about: protecting our brains ...

Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...